Storia in 2 fonti

ECO 2026: indirect comparison favours Wegovy pill over Foundayo - Pharmaceutical Technology

At ECO 2026, findings from a post-hoc indirect treatment comparison of Wegovy versus Foundayo, oral GLP-1RAs approved in the US for chronic weight management.

Raccontata da

fiercepharma.com

pharmaceutical-technology.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

pharmaceutical-technology.comStai leggendo1 mesi fa

ECO 2026: indirect comparison favours Wegovy pill over Foundayo - Pharmaceutical Technology

At ECO 2026, findings from a post-hoc indirect treatment comparison of Wegovy versus Foundayo, oral GLP-1RAs approved in the US for chronic weight management.

originale

fiercepharma.com1 mesi fa

The Oral GLP-1 Tracker: Wegovy pill total scripts down for first time

With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift toward oral GLP-1 drugs. | Fierce Pharma is launching the weekly Oral GLP-1 Tracker, leveraging…

Leggi questa versione → originale

Timeline cronologica

venerdì 15 maggio 2026·fiercepharma.com
The Oral GLP-1 Tracker: Wegovy pill total scripts down for first time
With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift toward oral GLP-1 drugs. | Fierce Pharma is launching the…
venerdì 15 maggio 2026·pharmaceutical-technology.com
ECO 2026: indirect comparison favours Wegovy pill over Foundayo - Pharmaceutical Technology
At ECO 2026, findings from a post-hoc indirect treatment comparison of Wegovy versus Foundayo, oral GLP-1RAs approved in the US for chronic weight management.